| Baseline characteristics | Placebo (n = 7) | Infliximab (n = 10) | p Value |
| Age (years) | 58 (27 to 60) | 51 (37 to 62) | 0.669 |
| Female, No (%) | 6 (85.7) | 8 (80.0) | 1.000 |
| Disease duration (months) | 9 (5 to 11) | 8 (6 to 10) | 0.740 |
| RF +ve, No (%) | 3 (42.9) | 7 (70.0) | 0.790 |
| PISA score | 3 (1 to 6) | 4 (2 to 6) | 0.294 |
| CCP +ve, No (%) | 4 (57.1) | 8 (80) | 1.000 |
| EMS | 90 (15 to 120) | 60 (30 to 280) | 0.740 |
| CRP | 23 (14 to 33) | 14.65 (5 to 52.25) | 0.669 |
| SJC66 | 5 (3 to 9) | 7 (3 to 20.5) | 0.536 |
| TJC68 | 3 (2 to 7) | 5 (2 to 13.5) | 0.408 |
| HAQ score | 0.875 (0.750 to 1.875) | 1.187 (0.968 to 2.125) | 0.364 |
| DAS28 | 4.30 (3.80 to 5.30) | 5.25 (3.23 to 6.48) | 0.669 |
| Pain VAS | 43 (15 to 60) | 41 (0 to 85) | 0.807 |
| Patient global VAS | 51 (23 to 67) | 55 (2 to 96) | 1.000 |
| Physician global VAS | 38 (15 to 53) | 50 (2 to 65) | 0.140 |
| Fatigue VAS | 51 (24 to 92) | 54 (0 to 90) | 0.732 |
Values are given as median (interquartile range).
No significant difference between the infliximab and placebo groups were observed for baseline measures.
CCP, cyclic citrullinated protein; CRP, C-reactive protein; DAS28, 28 joint Disease Activity Score; EMS, early morning stiffness; HAQ, Health Assessment Questionnaire; PISA, persistent inflammatory symmetrical arthritis; RF, rheumatoid factor; SJC66, number of swollen joints, of 66 joints assessed; TJC68, number of tender joints, of 68 joints assessed; VAS, visual analogue score along a 100 mm scale.